Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g., corticosteroids) are the mainstays of prescription AD treatment, and systemic immunomodulators are used to treat topical-refractory cases. Recent entrants from Pfizer (i.e., Eucrisa) and Sanofi/Regeneron (i.e., Dupixent) offer a new, nonsteroidal topical option and a targeted biologic for topical-refractory patients, respectively. This content explores how new therapies have fared and provides context for new players seeking to capitalize on the unmet needs in this sizable, underserved arena.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed adult patients with AD? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult patients with AD?
- How have Dupixent and Eucrisa been integrated into the AD treatment algorithm?
- What proportion of adult AD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of adult AD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated adults with AD?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
- United States
Longitudinal patient-level claims data analysis
KEY DRUGS COVERED
Dupixent, Eucrisa, Protopic, Elidel, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, key topical corticosteroids
KEY ANALYSIS PROVIDED
- Brand use across a longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.